Diabetes, Obesity and Metabolism10.1111/dom.146402022Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetesChristophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal,,
Diabetes Spectrum10.2337/ds16-00262017303202-210Glucagon-Like Peptide 1 Receptor Agonists for Type 2 DiabetesDeborah Hinnen,
Handbook of Incretin-based Therapies in Type 2 Diabetes10.1007/978-3-319-08982-9_3201631-43Glucagon-like peptide-1 receptor agonistsBaptist Gallwitz
Annals of Pediatric Endocrinology & Metabolism10.6065/apem.2017.22.1.15201722115Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetesSeungah Lee, Dong Yun Lee,,
Clinical Therapeutics10.1016/j.clinthera.2017.03.01320173961244-1264Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor AgonistsQiuhe Ji,
Canadian Journal of Diabetes10.1016/j.jcjd.2017.02.0032017WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 DiabetesJulie A. Lovshin,
Journal of Diabetes Investigation10.1111/jdi.129112018102196-201Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug developmentBo Ahrén,
Diabetes mellitus10.14341/dm88042017204286-298Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetesGagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovich,
Diabetes Care10.2337/dc11-s231201134Supplement_2S279-S284Long-Acting Glucagon-Like Peptide 1 Receptor AgonistsAlan J. Garber,
The Journal of Korean Diabetes10.4093/jkd.2018.19.1.35201819135Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes AssociationHyun Jin Kim,,